LONDON BROKER RATINGS: Berenberg cuts Fresnillo; Citi cuts Babcock
5th Feb 2026 09:48
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Friday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Friday: Read More
(Alliance News) - The FTSE 100 surged to a fresh high on Wednesday, spurred by strong trading updates and as insurer Beazley said it has accepted a possible GBP8.0 billion bid. Read More
(Alliance News) - Stock prices in London were higher at midday on Wednesday, despite ongoing jitters over the impact of the latest artificial intelligence developments, as Beazley, DCC and GSK helped the FTSE 100 reach a fresh record. Read More
(Alliance News) - GSK PLC on Wednesday backed guidance after fourth-quarter results beat expectations, driven by growth in its Specialty Medicines and Vaccines divisions and lower-than-expected expenses. Read More
(Alliance News) - Beazley agrees to takeover terms for a GBP8.0 billion takeover by Zurich Insurance, while GSK reports "another strong performance" helped by its Specialty Medicines arms. Read More
(Alliance News) - The FTSE 100 shrugged off a weak start, and further volatility in metals and oil prices, to hit new highs on Monday, amid optimism in the manufacturing sector on either side of the pond. Read More
(Alliance News) - Drugs firm GSK PLC is axing up to around 350 research and development jobs across the US and UK as part of an ongoing overhaul of the division. Read More
(Alliance News) - Stock prices in London closed mostly higher on Thursday, as investors digested the US Federal Reserve's Wednesday decision to stand pat on interest rates. Read More
(Alliance News) - Pharmaceutical firm AstraZeneca PLC on Thursday unveiled plans to invest USD15 billion in China through to 2030, in an announcement that coincides with UK Prime Minister Keir Starmer's visit to Beijing. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - The UK pub sector awaits a GBP100 million support package from the Treasury aimed at easing cost pressures, the Financial Times reports, while Sage posts 10% quarterly revenue growth and Dr Martens reports a dip in third-quarter revenue. Read More
(Alliance News) - GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. Read More
(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More
GSK PLC - London-based pharmaceuticals company - Says China's National Medical Products Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) in a new indication, for adults with uncontrolled asthma. This adds to the therapy's current licence for use in chronic obstructive pulmonary disease, and makes it the first and only single inhaler triple therapy approved for the maintenance treatment of both respiratory conditions in China. GSK says approval was based on its Captain study, "which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI." Says asthma is one of the most prevalent chronic respiratory diseases in China, with around 46 million adults affected and approximately half of patients experiencing uncontrolled symptoms. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More
(Alliance News) - Stock prices in London slid further on Tuesday morning for the second day, as tariff threats from the US continued to unsettle investors. Read More
(Alliance News) - GSK PLC on Tuesday announced the USD2.2 billion acquisition of RAPT Therapeutics Inc, a California-based clinical-stage biopharmaceutical company focused on novel therapies for inflammatory and immunologic diseases. Read More
(Alliance News) - The UK unemployment rate was steady while regular earnings growth slowed, GSK agrees to buy biopharmaceutical firm RAPT Therapeutics for USD2.2 billion and Informa reports "strong trading" in the fourth quarter. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More